Volume 5, Number 4—August 1999
Ofloxacin-Resistant Vibrio cholerae O139 in Hong Kong
To the Editor: Unexpected outbreaks of cholera occurred in many areas of the world in 1997-98, partly because of weather changes associated with the El Niño phenomenon (1). Outbreaks caused by antibiotic-resistant Vibrio cholerae O1 and O139 have been documented in the Indian subcontinent (2-4), Africa (5), and Ukraine (6).
In Hong Kong, nonduplicate bacterial strains of V. cholerae O1 and O139 isolated from patients and environmental sources and received in the Public Health Laboratory between January 1, 1993, and June 30, 1998, were identified by conventional biochemical tests (7,8) and API 20E (bioMerieux, France); serotyped by slide agglutination with polyvalent O1 and mono-specific Inaba and Ogawa antisera (Murex, Dartford, United Kingdom); and checked with O139 antiserum (Denka Seiken, Tokyo, Japan). Biotyped and antibiotic susceptibilities were determined by the Kirby-Bauer disk-diffusion assay (8-10). Antibiotics tested included chloramphenicol and tetracycline (from 1993 to 1996) and ofloxacin (added in routine testing from 1997). V. cholerae isolates available for further study were tested with the standard broth microdilution method (11) to measure minimum inhibitory concentrations (MICs) of susceptibilities to chloramphenicol, tetracycline, and ofloxacin.
No antibiotic resistance was seen in V. cholerae isolates in testing conducted from 1969 to 1995. The first V. cholerae isolate with reduced susceptibility to chloramphenicol but sensitive to tetracycline was encountered in Hong Kong in 1996. This O1 El Tor Ogawa strain was imported from Nepal. Since then, more O1 strains were isolated that exhibited reduced antibiotic susceptibilities to chloramphenicol and tetracycline but not to ofloxacin (12). In May 1998, seven V. cholerae O139 strains were isolated that displayed patterns of antibiotic susceptibilities strikingly different from those of O1 isolates; the former were all sensitive to tetracycline but showed reduced susceptibilities to chloramphenicol and ofloxacin. All V. cholerae O1 strains tested have been susceptible to ofloxacin; O1 isolates falling into intermediate categories for chloramphenicol and tetracycline susceptibilities (31% and 27.6%, respectively) were common.
The first isolate of V. cholerae O139 in Hong Kong came from the imported case of a patient who had traveled to other provinces of China (13,14). Isolation of O139 continued sporadically since then, with six cases between 1993 and the 1st quarter of 1998. In May 1998, a cluster of seven imported cases of V. cholerae O139 were reported with strains isolated from seven persons who became ill with severe diarrhea after visiting Zhuhai in Guangdong Province, China. Of 13 V. cholerae O139 isolates tested, 7 showed intermediate resistance to chloramphenicol and high-level resistance to ofloxacin (MIC 16 µg/ml) but no resistance to tetracycline (MIC 50s and MIC 90s were 0.25 µg/ml). This is the first evidence of a quinolone-resistant strain of V. cholerae O139 in Hong Kong. Of the O1 isolates, none were resistant to chloramphenicol and ofloxacin, but six were resistant to tetracycline (MIC 50s and MIC 90s were 0.25 µg/ml and 8 µg/ml, respectively).
Although all O1 isolates were sensitive to chloramphenicol, there was only a twofold difference in MIC90 to chloramphenicol between O1 and O139 isolates. MIC90s of ofloxacin for O139 were nearly 10 times higher than those for O1 strains.
The novel appearance of O139 resistant to ofloxacin with MICs of 16 µg/ml from Guangdong Province, China, was of special concern. Preliminary results using pulsed-field gel electrophoresis analysis of chromosomal DNA showed that these ofloxacin-resistant O139 strains had identical fingerprint patterns and probably belonged to the clone that had caused severe diarrheal disease in the region. Two previous surveys of V. cholerae antibiotic susceptibilities had not described any ofloxacin-resistant O139 strains (15,16). The potential for rapid spread of these strains threatens cholera prevention and control efforts that may still rely on chemotherapy.
Different antimicrobial resistance patterns of V. cholerae O1 and O139 were noted. Among the resistant O1 isolates, four were local, one was from other provinces of China, and one was from Thailand. All the resistant O139 isolates were imported from Guangdong Province, China. Antibiotic resistance was found in strains from local isolates and from neighboring countries. The unique patterns of antimicrobial resistance for the O1 and O139 isolates suggest different mechanisms of resistance. As quinolones are used heavily in this region to treat cholera and other enteric diseases, selective pressure could encourage emergence of ofloxacin resistance. Prudent use of antibiotics should be exercised during antimicrobial therapy and prophylaxis for cholera and other enteric diseases to decrease the selection of more resistant clones in our locality.
- World Health Organization. Geneva. Cholera in 1997. Wkly Epidemiol Rec. 1998;73:201–8.
- Gharagozloo RA, Naficy K, Mouin M, Nassirzadeh MH, Yalda R. Comparative trial of tetracycline, chloramphenicol, and trimethoprim/sulphamethoxazole in eradication of Vibrio cholerae El Tor. BMJ. 1970;4:281–2.
- Glass RI, Huq I, Alim AR, Yunus M. Emergence of multiply antibiotic-resistant Vibrio cholerae in Bangladesh. J Infect Dis. 1980;142:939–42.
- Ramamurthy T, Garg S, Sharma R, Bhattacharya SK, Nair GB, Shimada T, Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet. 1993;341:703–4.
- Finch MJ, Morris JG Jr, Kaviti J, Kagwanja W, Levine MM. Epidemiology of antimicrobial resistant cholera in Kenya and east Africa. Am J Trop Med Hyg. 1988;39:484–90.
- Clark CG, Kravetz AN, Alekseenko VV, Krendelev YD, Johnson WM. Microbiological and epidemiological investigation of cholera epidemic in Ukraine during 1994 and 1995. Epidemiol Infect. 1998;121:1–13.
- Cowan ST, Steel KJ. Manual for the identification of medical bacteria. 2nd ed. Cambridge: Cambridge University Press; 1974.
- Bradfold AK, Bopp CA, Wells JG. Isolation and identification of Vibrio cholerae O1 from fecal specimens. In: Wachsmuth IK, Blake AB, Olsvik Ø, editors. Vibrio cholerae and cholera: molecular to global perspectives. Washington: American Society for Microbiology; 1994. p. 3-26.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests approved standard. NCCLS document M2-A6. Villanova (PA): The Committee; 1997.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; NCCLS document M100-S8, 18(1). Villanova (PA): The Committee; 8th information supplement, 1998.
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. NCCLS document M7-A4. Villanova (PA): The Committee; 1997.
- Wong W, Ho YY. Imported cholera cases among tours returning from Thailand. Public Health & Epidemiology Bulletin. Department of Health, Hong Kong. 1998;7:21–4.
- Kam KM, Leung TH, Ho PYY, Ho KY, Saw TA. Outbreak of Vibrio cholerae O1 in Hong Kong related to contaminated fish tank water. Public Health. 1995;109:389–95.
- Lee SH, Lai ST, Lai JY, Leung NK. Resurgence of cholera in Hong Kong. Epidemiol Infect. 1996;117:43–9.
- Yamamoto T, Nair GB, Albert MJ, Parodi CC, Takeda Y. Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents. Antimicrob Agents Chemother. 1995;39:241–4.
- Sciortino CV, Johnson JA, Hamad A. Vitek system antimicrobial susceptibility testing of O1, O139, and non-O1 Vibrio cholerae. J Clin Microbiol. 1996;34:897–900.
Suggested citation: Kam KM, Luey KY, Cheung TL, Ho KY, Mak KH, Saw PTA. Ofloxacin-Resistant Vibrio cholerae O139 in Hong Kong [letter]. Emerg Infect Dis [serial on the Internet]. 1999, Aug [date cited]. Available from http://wwwnc.cdc.gov/eid/article/5/4/99-0431
- Page created: December 13, 2010
- Page last updated: December 13, 2010
- Page last reviewed: December 13, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)